MedPath

Cetirizine

Generic Name
Cetirizine
Brand Names
Aller-tec, Aller-tec D, Quzyttir, Reactine, Wal Zyr 24 Hour Allergy, Wal Zyr D, Wal-zyr, Zerviate, Zyrtec, Zyrtec-D
Drug Type
Small Molecule
Chemical Formula
C21H25ClN2O3
CAS Number
83881-51-0
Unique Ingredient Identifier
YO7261ME24
Background

Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , .

One of the most common uses for this drug is for a condition called allergic rhinitis. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects .

Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects .

Indication

Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes .

Perennial allergic rhinitis: This drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing .

Chronic urticaria: Cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It markedly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus .

Associated Conditions
Allergy to Tree Pollen, Chronic Idiopathic Urticaria, Flu caused by Influenza, Perennial Allergic Rhinitis (PAR), Respiratory Allergy, Seasonal Allergic Rhinitis

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Phase 3
Completed
Conditions
Lower Ureteric Stones
Interventions
Combination Product: Cetirizine + Tamsulosin
Other: Placebo
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
South Valley University
Target Recruit Count
480
Registration Number
NCT06754410
Locations
🇪🇬

Qena university hospital, Qena, Egypt

Organ Protective Effect of Cetirizine In Patients With Severe Burns

Phase 1
Recruiting
Conditions
Burns
Interventions
First Posted Date
2023-11-13
Last Posted Date
2024-02-01
Lead Sponsor
Ruijin Hospital
Target Recruit Count
32
Registration Number
NCT06126991
Locations
🇨🇳

Department of Burn, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

The Effect of Switching the H1-antagonist Clemastine to Cetirizine in Premedication Regimens During Paclitaxel Treatment

Completed
Conditions
Solid Tumor
Interventions
First Posted Date
2023-09-15
Last Posted Date
2024-02-20
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
395
Registration Number
NCT06039137
Locations
🇳🇱

Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Phase 4
Completed
Conditions
Fabry's Disease
Interventions
First Posted Date
2023-08-31
Last Posted Date
2025-02-26
Lead Sponsor
Sanofi
Target Recruit Count
8
Registration Number
NCT06019728
Locations
🇺🇸

UCLA Medical Center Site Number : 1003, Santa Monica, California, United States

🇺🇸

Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States

🇺🇸

Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States

and more 2 locations

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

First Posted Date
2023-07-14
Last Posted Date
2024-08-21
Lead Sponsor
Emory University
Target Recruit Count
5
Registration Number
NCT05946551
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 1 locations

The Effect of Cetirizine HCl on Exercise-induced Arterial Hypoxemia in Highly-trained Swimmers

Phase 4
Terminated
Conditions
Exercise-induced Arterial Hypoxemia
Interventions
Other: Placebo
First Posted Date
2021-10-27
Last Posted Date
2024-03-05
Lead Sponsor
Indiana University
Target Recruit Count
16
Registration Number
NCT05095311
Locations
🇺🇸

1025 E Seventh St, Bloomington, Indiana, United States

Cetirizine and Famotidine for COVID-19

Phase 4
Withdrawn
Conditions
Covid19
Interventions
First Posted Date
2021-04-08
Last Posted Date
2021-08-20
Lead Sponsor
Emory University
Registration Number
NCT04836806
Locations
🇺🇸

Emory University Hospital at Wesley Woods COVID-19 Testing Facility, Atlanta, Georgia, United States

🇺🇸

Emory Healthcare Network Peachtree Immediate Care COVID-19 Testing Centers, Atlanta, Georgia, United States

Topical Cetirizine in Androgenetic Alopecia in Females

Phase 2
Completed
Conditions
Androgenetic Alopecia
Interventions
First Posted Date
2020-07-22
Last Posted Date
2023-02-08
Lead Sponsor
Cairo University
Target Recruit Count
66
Registration Number
NCT04481412
Locations
🇪🇬

Al-Kasr Al-Ainy outpatient dermatology clinic, Cairo, ِAl-Kasr Al-Ainy, Egypt

Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

Phase 4
Conditions
Androgenetic Alopecia
Interventions
First Posted Date
2020-03-03
Last Posted Date
2020-03-04
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT04293822
Locations
🇪🇬

Assiut University, Assiut, Egypt

Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel

Phase 3
Completed
Conditions
Lung Cancer
Ovarian Cancer
Breast Cancer
Oesophageal Cancer
Head Cancer Neck
Cervical Cancer
Endometrial Cancer
Interventions
First Posted Date
2020-01-22
Last Posted Date
2020-10-12
Lead Sponsor
Ciusss de L'Est de l'Île de Montréal
Target Recruit Count
27
Registration Number
NCT04237090
Locations
🇨🇦

CIUSSS de l'Est-de-l'île-de-Montréal, Montréal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath